Teva Pharmaceutical Industries Ltd (TEVA) - Total Assets
Based on the latest financial reports, Teva Pharmaceutical Industries Ltd (TEVA) holds total assets worth ILA40.76 Billion ILA (≈ $109.27 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See TEVA net assets for net asset value and shareholders' equity analysis.
Teva Pharmaceutical Industries Ltd - Total Assets Trend (1985–2025)
This chart illustrates how Teva Pharmaceutical Industries Ltd's total assets have evolved over time, based on quarterly financial data.
Teva Pharmaceutical Industries Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Teva Pharmaceutical Industries Ltd's total assets of ILA40.76 Billion consist of 34.2% current assets and 65.8% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 8.7% |
| Accounts Receivable | ILA3.71 Billion | 9.1% |
| Inventory | ILA3.18 Billion | 7.8% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA3.78 Billion | 9.3% |
| Goodwill | ILA16.00 Billion | 39.3% |
Asset Composition Trend (1985–2025)
This chart illustrates how Teva Pharmaceutical Industries Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Teva Pharmaceutical Industries Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Teva Pharmaceutical Industries Ltd's current assets represent 34.2% of total assets in 2025, a decrease from 61.8% in 1985.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2025, down from 16.1% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is goodwill at 39.3% of total assets.
Teva Pharmaceutical Industries Ltd Competitors by Total Assets
Key competitors of Teva Pharmaceutical Industries Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277
|
China | CN¥1.77 Billion |
Teva Pharmaceutical Industries Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.04 | 0.98 | 1.03 |
| Quick Ratio | 0.80 | 0.75 | 0.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA490.10 Million | ILA-244.00 Million | ILA312.00 Million |
Teva Pharmaceutical Industries Ltd - Advanced Valuation Insights
This section examines the relationship between Teva Pharmaceutical Industries Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.42 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 3.6% |
| Total Assets | ILA40.76 Billion |
| Market Capitalization | $1.09 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Teva Pharmaceutical Industries Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Teva Pharmaceutical Industries Ltd's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Teva Pharmaceutical Industries Ltd (1985–2025)
The table below shows the annual total assets of Teva Pharmaceutical Industries Ltd from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ILA40.76 Billion ≈ $109.27 Million |
+3.64% |
| 2024-12-31 | ILA39.33 Billion ≈ $105.43 Million |
-9.55% |
| 2023-12-31 | ILA43.48 Billion ≈ $116.57 Million |
-1.20% |
| 2022-12-31 | ILA44.01 Billion ≈ $117.98 Million |
-7.68% |
| 2021-12-31 | ILA47.67 Billion ≈ $127.79 Million |
-5.87% |
| 2020-12-31 | ILA50.64 Billion ≈ $135.76 Million |
-11.88% |
| 2019-12-31 | ILA57.47 Billion ≈ $154.08 Million |
-5.29% |
| 2018-12-31 | ILA60.68 Billion ≈ $162.69 Million |
-14.07% |
| 2017-12-31 | ILA70.61 Billion ≈ $189.32 Million |
-23.98% |
| 2016-12-31 | ILA92.89 Billion ≈ $249.03 Million |
+71.20% |
| 2015-12-31 | ILA54.26 Billion ≈ $145.46 Million |
+16.88% |
| 2014-12-31 | ILA46.42 Billion ≈ $124.45 Million |
-2.29% |
| 2013-12-31 | ILA47.51 Billion ≈ $127.37 Million |
-6.13% |
| 2012-12-31 | ILA50.61 Billion ≈ $135.68 Million |
+0.93% |
| 2011-12-31 | ILA50.14 Billion ≈ $134.43 Million |
+28.40% |
| 2010-12-31 | ILA39.05 Billion ≈ $104.70 Million |
+15.50% |
| 2009-12-31 | ILA33.81 Billion ≈ $90.64 Million |
+2.75% |
| 2008-12-31 | ILA32.90 Billion ≈ $88.21 Million |
+40.54% |
| 2007-12-31 | ILA23.41 Billion ≈ $62.77 Million |
+14.37% |
| 2006-12-31 | ILA20.47 Billion ≈ $54.88 Million |
+97.08% |
| 2005-12-31 | ILA10.39 Billion ≈ $27.85 Million |
+7.84% |
| 2004-12-31 | ILA9.63 Billion ≈ $25.82 Million |
+62.82% |
| 2003-12-31 | ILA5.92 Billion ≈ $15.86 Million |
+27.86% |
| 2002-12-31 | ILA4.63 Billion ≈ $12.40 Million |
+33.72% |
| 2001-12-31 | ILA3.46 Billion ≈ $9.28 Million |
+21.17% |
| 2000-12-31 | ILA2.86 Billion ≈ $7.66 Million |
+66.60% |
| 1999-12-31 | ILA1.71 Billion ≈ $4.60 Million |
+19.36% |
| 1998-12-31 | ILA1.44 Billion ≈ $3.85 Million |
+20.83% |
| 1997-12-31 | ILA1.19 Billion ≈ $3.19 Million |
-4.27% |
| 1996-12-31 | ILA1.24 Billion ≈ $3.33 Million |
+42.48% |
| 1995-12-31 | ILA871.30 Million ≈ $2.34 Million |
+28.89% |
| 1994-12-31 | ILA676.00 Million ≈ $1.81 Million |
+20.09% |
| 1993-12-31 | ILA562.90 Million ≈ $1.51 Million |
+26.49% |
| 1992-12-31 | ILA445.00 Million ≈ $1.19 Million |
+18.13% |
| 1991-12-31 | ILA376.70 Million ≈ $1.01 Million |
+9.57% |
| 1990-12-31 | ILA343.80 Million ≈ $921.72K |
+19.92% |
| 1989-12-31 | ILA286.70 Million ≈ $768.63K |
+15.56% |
| 1988-12-31 | ILA248.10 Million ≈ $665.15K |
+73.74% |
| 1986-12-31 | ILA142.80 Million ≈ $382.84K |
+2.66% |
| 1985-12-31 | ILA139.10 Million ≈ $372.92K |
-- |
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more